NASDAQ:ASLN ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis $0.60 0.00 (0.00%) As of 07/2/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About ASLAN Pharmaceuticals Stock (NASDAQ:ASLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ASLAN Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.60▼$0.6050-Day Range$0.60▼$0.6052-Week Range$0.48▼$25.44VolumeN/AAverage Volume122,322 shsMarket Capitalization$1.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ASLAN Pharmaceuticals Ltd is a clinical‐stage biotechnology company focused on the discovery and development of novel immunology and oncology therapies. The company leverages proprietary antibody and small‐molecule platforms to address critical biological targets involved in tumor immune evasion and inflammatory disease pathways. ASLAN’s R&D approach combines modern protein engineering, antibody-drug conjugates and precision small‐molecule design to generate next‐generation therapeutics. The company’s lead clinical programs include ASLAN003, an orally available allosteric IRAK4 inhibitor designed to modulate innate immune signaling in severe inflammatory diseases, and ASLAN004, a high-affinity nanobody targeting the CD39 ectonucleotidase to reinvigorate anti-tumor immune responses. In addition to these assets, ASLAN is advancing a diversified preclinical pipeline that features antibody-drug conjugates for solid tumors and multi-specific antibody formats aimed at difficult-to-treat cancers. Founded in Singapore in 2015, ASLAN has established operations across Asia, Australia and the United States to support global clinical development. The company completed its initial public offering on the Nasdaq in 2020 and maintains a management team with extensive leadership experience in biopharmaceutical research, regulatory affairs and commercial strategy. ASLAN continues to pursue strategic partnerships and clinical collaborations to accelerate its programs toward regulatory milestones and potential market authorization.AI Generated. May Contain Errors. Read More Receive ASLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASLN Stock News HeadlinesHead-To-Head Survey: Eliem Therapeutics (NASDAQ:ELYM) and ASLAN Pharmaceuticals (NASDAQ:ASLN)June 25, 2026 | americanbankingnews.comPublic Health News | Today's Latest Stories | ReutersOctober 3, 2024 | reuters.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.July 5 at 1:00 AM | Weiss Ratings (Ad)ASLAN stock tumbles 54% after board votes to liquidateJuly 19, 2024 | msn.comWhy ASLAN Pharmaceuticals (ASLN) Shares Are Down 40%July 19, 2024 | msn.comWhy ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionJuly 19, 2024 | msn.comASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary LiquidationJuly 17, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to AppealJuly 15, 2024 | globenewswire.comSee More Headlines ASLN Stock Analysis - Frequently Asked Questions How have ASLN shares performed this year? ASLAN Pharmaceuticals' stock was trading at $0.60 at the beginning of 2026. Since then, ASLN shares have increased by 0.0% and is now trading at $0.60. How were ASLAN Pharmaceuticals' earnings last quarter? ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) posted its earnings results on Friday, August, 11th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($6.40) by $5.52. The business earned $12 million during the quarter. When did ASLAN Pharmaceuticals' stock split? ASLAN Pharmaceuticals shares reverse split on Wednesday, July 3rd 2024.The 1-8 reverse split was announced on Wednesday, July 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did ASLAN Pharmaceuticals IPO? ASLAN Pharmaceuticals (ASLN) raised $60 million in an initial public offering (IPO) on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers. How do I buy shares of ASLAN Pharmaceuticals? Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ASLAN Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ASLAN Pharmaceuticals investors own include Tesla (TSLA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Meta Platforms (META), Zoom Communications (ZM), Fulgent Genetics (FLGT) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/11/2023Today7/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASLN CIK1722926 Webwww.aslanpharma.com Phone65-6817-9598Fax65-6225-2419Employees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($21.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.22 million Net MarginsN/A Pretax Margin-290.83% Return on Equity-8,454.87% Return on Assets-121.60% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual Sales$12 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value($6.50) per share Price / Book-0.09Miscellaneous Outstanding Shares2,044,000Free Float1,948,000Market Cap$1.23 million OptionableNo Data Beta1.40 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ASLN) was last updated on 7/5/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ASLAN Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
